CLINICAL_TRIALS
trial_result
· 2022-12-14
Clinical Trial Update: CellFX Treat & Resect Low-Risk BCC Feasibility Study [NA]
Summary
Feasibility study update for CellFX treatment and resection in low-risk basal cell carcinoma completed with posted results in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pulse Biosciences, Inc. | Conditions: BCC - Basal Cell Carcinoma, BCC | NA | Status: COMPLETED | Results posted: 2022-12-14